Skip to main content
. 2022 Dec 12;12:1042525. doi: 10.3389/fonc.2022.1042525

Figure 4.

Figure 4

CT-scan performed in August 2021, after lenvatinib discontinuation, showing a dimensional increase of left thyroid lobe (4,9x3,7 cm) (A), latero-cervical lymphadenopathies (maximum diameter of 3 cm) (B) and multiple brain and cerebellar metastases (C).